Full-Time

Quality Operations Manager

Confirmed live in the last 24 hours

iRhythm Technologies

iRhythm Technologies

1,001-5,000 employees

Advanced cardiac monitoring solutions provider

Compensation Overview

$117.2k - $170.7k/yr

Senior

Highland Park, IL, USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Risk Management
Requirements
  • Bachelor's degree required in Science, Engineering, Computer Science, or related medical/science/healthcare field; or equivalent experience.
  • Minimum of 7 years of professional experience in quality and regulatory roles in the medical device field
  • Strong knowledge of medical device, GMPs, design control and risk management processes and regulations, including software as a medical device.
  • Previous experience working in highly regulated environments working with regulatory directly with agencies such as FDA and EU Notified Bodies
  • Previous knowledge of regulations and standards such as ISO 13485, ISO14971, FDA 21 CFR 820
  • Previous experience with participation in and or hosting external regulatory and or third-party audits.
  • High-level analytical skills and ability to focus on detail.
  • Proven capacity to collaborate and build positive relationships and trust over time with cross-functional partners.
  • Demonstrated comfort working in a dynamic, entrepreneurial environment where strong organizational, leadership and communication skills are required to be successful.
Responsibilities
  • Oversee the management of the day-to-day site Quality Operations activities which include: Quality Control, Reverse Logistics including intake operations, Product quality issues investigations, planned deviations and non-conformances, Complaint Investigations, as applicable, Calibration, as applicable.
  • Responsible for site Non-Conformance and MRB processes
  • Responsible for site calibration processes
  • Responsible for the execution of site-specific inspection readiness programs
  • Define & Monitor Site Quality Operations, metrics to drive product and system quality improvements
  • Ensures the implementation of site Quality Management system, standards and policies in alignment with iRhythm’s global quality management system.
  • Collaborate closely with clinical operations supporting the development of procedures and ensuring appropriate execution of operating within the quality management system.
  • Liaison with the iRhythm Independent Diagnostic Testing Facility (IDTF)
  • Collaborate closely with production and supply chain business partners to ensure a robust and fully compliant site Quality Management System.
  • Establish and improve systems to monitor and improve site product quality and lead site quality improvement initiatives.
  • Participate, and or lead/host site external audits such as FDA inspections and Notified Body audits,
  • Represent area of responsibility in meetings with management.
  • Contribute to efforts to maintain a positive quality culture, with operations fully acting as a business partners, while advocating for patients and customers’ needs.
  • Assume additional responsibilities and performs other duties as assigned.

iRhythm Technologies focuses on cardiac monitoring solutions, particularly through its Zio Patch, a wearable device that tracks heart rhythms for up to 14 days. This extended monitoring helps healthcare providers detect irregular heart rhythms that shorter monitoring periods might miss, making it easier for patients to monitor their heart health without frequent office visits. The company generates revenue by selling the Zio Patch and offering data analysis services to healthcare providers, enhancing their diagnostic capabilities. iRhythm differentiates itself by providing comprehensive cardiac monitoring solutions that improve patient outcomes and streamline healthcare workflows.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2006

Simplify Jobs

Simplify's Take

What believers are saying

  • iRhythm's expansion into Europe and Japan opens new market opportunities.
  • The wearable medical device market is growing at a 23.1% CAGR until 2030.
  • Integration with EHRs streamlines data sharing and improves patient care.

What critics are saying

  • Increased competition from AI-driven startups threatens iRhythm's market share.
  • FDA warning letter may lead to increased regulatory scrutiny.
  • Shareholder investigation for alleged securities fraud could have legal repercussions.

What makes iRhythm Technologies unique

  • Zio Patch offers up to 14 days of uninterrupted cardiac monitoring.
  • iRhythm integrates AI for predictive analytics in cardiac monitoring.
  • Zio Patch is the smallest and least conspicuous cardiac arrhythmia diagnostic device.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Mental Health Support

Hybrid Work Options

Pet Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

1%
ETF Daily News
Mar 26th, 2025
Cibc World Markets Corp Invests $264,000 in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Cibc World Markets Corp invests $264,000 in iRhythm Technologies, Inc. (NASDAQ:IRTC).

Investing.com
Feb 28th, 2025
iRhythm technologies' CBO and CLO Murphy sells $1.79 million in stock

Additionally, iRhythm is expanding internationally, with early launches in Europe and plans to enter the Japanese market in mid-2025.

Yahoo Finance
Jan 13th, 2025
Irhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights And Business Update At The 43Rd Annual J.P. Morgan Healthcare Conference

iRhythmSAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced preliminary fourth quarter operational highlights and a business update at the 43rd Annual J.P. Morgan Healthcare Conference.Recent Operational Highlights and Financial OutlookAnticipate full year 2024 revenue slightly above high end of previously stated guidance range of $587.5 million provided in October 2024Record quarter of new account openings for both Zio monitor and Zio AT during the fourth quarter 2024 as well as strong volume contributions from large national accountsLaunched first four health care systems on Epic Aura during the fourth quarter 2024 with broad commercial roll out for Epic health systems across the U.S. beginning in 2025Initiated Zio monitor shipments for home enrollment patients during the fourth quarter 2024Five studies presented at the American Heart Association highlight Zio Monitor’s high patient satisfaction, engagement and compliance with the patient MyZio app and digital tools, health economic impact of early arrhythmia detection in type 2 diabetes and respiratory disease, and AI insights on sleep and activity patterns 1Expect revenue for the full year 2025 of approximately $675 million to $685 million“This past year was a period of significant growth and transformation for iRhythm,” said Quentin Blackford, iRhythm’s President and CEO. “In our core U.S

MarketBeat
Nov 26th, 2024
Dynamic Technology Lab Private Ltd Invests $1.50 Million in iRhythm Technologies, Inc. (NASDAQ:IRTC)

Dynamic Technology Lab Private Ltd invests $1.50 million in iRhythm Technologies, Inc. (NASDAQ:IRTC).

MPO Magazine
Oct 22nd, 2024
iRhythm Earns FDA Nod for Zio AT After Warning Letter

The letter accused iRhythm of violating Federal Food, Drug, and Cosmetic Act rules about labeling, medical device reporting, and quality systems.